DNA markers for predicting outcomes in urothelial cancer
Part of Cancer, Kidney & urinary clinical trials.
This trial studies DNA markers in tumor tissue or blood samples to see if they can predict how well treatments work or how the cancer behaves. It may help doctors better understand and manage urothelial cancer in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have locally advanced or metastatic urothelial cancer, meaning cancer that has spread beyond the bladder or to other parts of the body.
- You must have tumor tissue available from a past surgery or biopsy.
- You must be willing to sign a consent form to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a simple, non-invasive blood test to find genetic markers for urinary tract cancers. It's for people newly diagnosed who haven't started treatment yet.
This study checks tumor DNA found in blood and urine to see who is at higher risk of the cancer coming back after surgery. It may help doctors identify “minimal residual disease,” meaning tiny amounts of cancer that can remain after treatment.
This study looks at blood tests to find pieces of tumor DNA (called ctDNA) in people with high-grade upper tract urothelial cancer (UTUC). It aims to see if these blood tests can help track the cancer's response to treatment or surgery, potentially guiding better care.
This trial tests a urine test that looks for tumor DNA to help doctors decide when you need a cystoscopy (a scope in the bladder). It is for people with high-risk or very high-risk non-muscle-invasive bladder cancer who have already had surgery to remove all visible tumors.
This study looks for specific DNA changes in bladder cancer tumors using a precise test. It aims to better understand the disease and may help guide future treatment choices.
This study uses a urine test to detect small amounts of cancer DNA (microscopic residual disease) after treatment, to see if it can catch a recurrence earlier than standard scans or cystoscopy. It includes four groups of people with different types and stages of urothelial cancer (in the kidney, ureter, or bladder) to see how well the test works for each group.
Hear when a new Urothelial Neoplasm trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.